Beyond BCG: Exploring Evolving Therapies for Intermediate-Risk Bladder Cancer - CME - Guideline Central

CME

Title
Beyond BCG: Exploring Evolving Therapies for Intermediate-Risk Bladder Cancer
Link
Description
This activity will cover the management of intermediate risk NMIBC, including diagnostic strategies, treatment advancements, BCG refractory cases, adjuvant therapies, with insights from leading experts in oncology and urology.
Target Audience
This activity is designed to meet the educational needs of Urologists, Urologic Oncologists, Medical Oncologists, Palliative Care, Pathologists, Advanced Practice Providers, Nurse Navigators and other healthcare professionals who treat patients with intermediate risk NMIBC.
Learning Objectives
  • Employ strategies to enhance diagnostic accuracy for intermediate-risk bladder cancer, including applying risk stratification tools and integrating biomarkers into clinical workflows.
  • Evaluate and implement alternative therapies to Bacillus Calmette-Guérin (BCG), including intravesical mitomycin, sustained-release formulations, and novel immunologic or gene therapies.
  • Describe evidence-based surveillance protocols, balancing the need for disease monitoring with considerations of patient burden and healthcare costs.
  • Understand the clinical utility of urinary biomarkers in predicting recurrence, guiding treatment selection, and monitoring treatment response in intermediate-risk bladder cancer.
  • Recognize the importance of multidisciplinary care, fostering collaboration among urologists, oncologists, radiologists, and pathologists to optimize treatment planning and patient outcomes.
  • Develop patient-centered treatment plans, tailoring therapy to individual clinical profiles while considering patient preferences and quality of life
Estimated Duration
120 minutes
Delivery Mode
Online
Format
Online Learning
Specialties
Oncology, Pathology, Hospice and Palliative Medicine, Urology
Keywords
bladder cancer, intermediate risk NMIBC
Disclosures and Disclaimers
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Accredited Providers
  • Postgraduate Institute for Medicine
Commercial Support
  • UroGen Pharma, Inc
Activity Expiration Date
February 1, 2027
Credit Information
Credit TypeUnits / Unit TypeBoard
AMA PRA Category 1 Credit2 CreditsACCME- Accreditation Council for Continuing Medical Education
Nursing2 Contact Hours—
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.